JP2026012786A5 - - Google Patents
Info
- Publication number
- JP2026012786A5 JP2026012786A5 JP2025174910A JP2025174910A JP2026012786A5 JP 2026012786 A5 JP2026012786 A5 JP 2026012786A5 JP 2025174910 A JP2025174910 A JP 2025174910A JP 2025174910 A JP2025174910 A JP 2025174910A JP 2026012786 A5 JP2026012786 A5 JP 2026012786A5
- Authority
- JP
- Japan
- Prior art keywords
- methods
- new products
- manufacturing methods
- manufacturing
- methods substantially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130076P | 2015-03-09 | 2015-03-09 | |
| US62/130,076 | 2015-03-09 | ||
| JP2022051047A JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022072043A JP7403575B2 (ja) | 2015-03-09 | 2022-04-26 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2023209102A JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209102A Division JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026012786A JP2026012786A (ja) | 2026-01-27 |
| JP2026012786A5 true JP2026012786A5 (https=) | 2026-02-18 |
Family
ID=55863122
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547456A Pending JP2018509413A (ja) | 2015-03-09 | 2016-03-08 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2021016293A Active JP7050191B2 (ja) | 2015-03-09 | 2021-02-04 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022051047A Active JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022072043A Active JP7403575B2 (ja) | 2015-03-09 | 2022-04-26 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2023209102A Active JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2025174910A Pending JP2026012786A (ja) | 2015-03-09 | 2025-10-16 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547456A Pending JP2018509413A (ja) | 2015-03-09 | 2016-03-08 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2021016293A Active JP7050191B2 (ja) | 2015-03-09 | 2021-02-04 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022051047A Active JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022072043A Active JP7403575B2 (ja) | 2015-03-09 | 2022-04-26 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2023209102A Active JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160264669A1 (https=) |
| EP (2) | EP4006051A1 (https=) |
| JP (6) | JP2018509413A (https=) |
| KR (1) | KR102720769B1 (https=) |
| AU (2) | AU2016230827B2 (https=) |
| CA (1) | CA2978253A1 (https=) |
| DK (1) | DK3268391T3 (https=) |
| EA (1) | EA038178B1 (https=) |
| ES (1) | ES2882999T3 (https=) |
| HU (1) | HUE056775T2 (https=) |
| IL (2) | IL295425A (https=) |
| LT (1) | LT3268391T (https=) |
| MX (2) | MX386491B (https=) |
| MY (1) | MY188761A (https=) |
| PL (1) | PL3268391T3 (https=) |
| PT (1) | PT3268391T (https=) |
| SG (2) | SG11201707053SA (https=) |
| WO (1) | WO2016142782A1 (https=) |
| ZA (1) | ZA202109042B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112142843B (zh) | 2013-12-24 | 2024-10-18 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| KR20250052465A (ko) * | 2015-01-30 | 2025-04-18 | 모멘타 파머슈티컬스 인코포레이티드 | ＦｃＲｎ 항체 및 이의 사용 방법 |
| MY188761A (en) * | 2015-03-09 | 2021-12-29 | Argenx Bvba | Method of reducing serum levels of fc-containing agents using fcrn antagonists |
| AU2017292184A1 (en) | 2016-07-08 | 2019-02-07 | Staten Biotechnology B.V. | Anti-Apoc3 antibodies and methods of use thereof |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| KR20200074975A (ko) | 2017-10-31 | 2020-06-25 | 스태튼 바이오테크놀로지 비.브이. | 항-ApoC3 항체 및 이의 사용 방법 |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| US12240875B2 (en) * | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| CA3101462A1 (en) | 2018-06-08 | 2019-12-12 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
| WO2020148336A1 (en) * | 2019-01-16 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| CN114126647A (zh) * | 2019-06-07 | 2022-03-01 | 阿尔金克斯有限公司 | 适用于皮下施用的FcRn抑制剂的药物制剂 |
| EP4004039A2 (en) * | 2019-07-25 | 2022-06-01 | Genzyme Corporation | Methods of treating antibody-mediated disorders with fcrn antagonists |
| BR112022013554A2 (pt) | 2020-01-08 | 2022-09-06 | argenx BV | Métodos para tratar distúrbios do pênfigo |
| CN114341184B (zh) * | 2020-02-10 | 2023-04-04 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US20230220069A1 (en) * | 2020-06-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| US20250136699A1 (en) * | 2021-08-13 | 2025-05-01 | Jiangsu Biojetay Biotechnology Co., Ltd. | Antibodies specifically recognizing fcrn and uses thereof |
| CA3258000A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE |
| KR20250109198A (ko) * | 2022-11-14 | 2025-07-16 | 아르젠엑스 비브이 | Fcrn 길항제 분자 및 이의 사용 방법 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6992234B2 (en) * | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| CA2467781C (en) | 2000-11-20 | 2014-09-23 | Canadian Blood Services | Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| DE60334141D1 (de) | 2002-10-15 | 2010-10-21 | Facet Biotech Corp | VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| WO2004062619A2 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| MY173526A (en) * | 2009-03-25 | 2020-01-31 | Genentech Inc | Novel anti-?5?1 antibodies and uses thereof |
| SG10201603962TA (en) | 2011-05-25 | 2016-07-28 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders |
| CA2853637C (en) * | 2011-10-26 | 2023-04-04 | Novartis Ag | Anti-canine cd20 monoclonal antibodies and methods of use |
| EP2780463A4 (en) * | 2011-11-18 | 2015-07-01 | Merck Sharp & Dohme | FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING |
| DK3421486T5 (da) | 2012-06-22 | 2024-09-16 | The Trustees Of Darthmouth College | Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser |
| CN112142843B (zh) * | 2013-12-24 | 2024-10-18 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| MY188761A (en) * | 2015-03-09 | 2021-12-29 | Argenx Bvba | Method of reducing serum levels of fc-containing agents using fcrn antagonists |
-
2016
- 2016-03-08 MY MYPI2017001178A patent/MY188761A/en unknown
- 2016-03-08 SG SG11201707053SA patent/SG11201707053SA/en unknown
- 2016-03-08 HU HUE16719896A patent/HUE056775T2/hu unknown
- 2016-03-08 IL IL295425A patent/IL295425A/en unknown
- 2016-03-08 ES ES16719896T patent/ES2882999T3/es active Active
- 2016-03-08 DK DK16719896.9T patent/DK3268391T3/da active
- 2016-03-08 EP EP21189336.7A patent/EP4006051A1/en active Pending
- 2016-03-08 PL PL16719896T patent/PL3268391T3/pl unknown
- 2016-03-08 CA CA2978253A patent/CA2978253A1/en active Pending
- 2016-03-08 US US15/064,195 patent/US20160264669A1/en active Pending
- 2016-03-08 JP JP2017547456A patent/JP2018509413A/ja active Pending
- 2016-03-08 KR KR1020177027256A patent/KR102720769B1/ko active Active
- 2016-03-08 PT PT167198969T patent/PT3268391T/pt unknown
- 2016-03-08 IL IL254403A patent/IL254403B/en unknown
- 2016-03-08 EA EA201791984A patent/EA038178B1/ru unknown
- 2016-03-08 EP EP16719896.9A patent/EP3268391B1/en active Active
- 2016-03-08 WO PCT/IB2016/000398 patent/WO2016142782A1/en not_active Ceased
- 2016-03-08 SG SG10201908259W patent/SG10201908259WA/en unknown
- 2016-03-08 AU AU2016230827A patent/AU2016230827B2/en active Active
- 2016-03-08 LT LTEPPCT/IB2016/000398T patent/LT3268391T/lt unknown
- 2016-03-08 MX MX2017011534A patent/MX386491B/es unknown
-
2017
- 2017-09-08 MX MX2021011633A patent/MX2021011633A/es unknown
-
2021
- 2021-02-04 JP JP2021016293A patent/JP7050191B2/ja active Active
- 2021-11-15 ZA ZA2021/09042A patent/ZA202109042B/en unknown
- 2021-12-02 AU AU2021277720A patent/AU2021277720B2/en active Active
-
2022
- 2022-03-28 JP JP2022051047A patent/JP7391132B2/ja active Active
- 2022-04-26 JP JP2022072043A patent/JP7403575B2/ja active Active
-
2023
- 2023-12-12 JP JP2023209102A patent/JP7823011B2/ja active Active
-
2025
- 2025-10-16 JP JP2025174910A patent/JP2026012786A/ja active Pending